Using ALK+ lung cancer patient-derived cell lines, researchers have performed phosphoproteomic screening and identified guanylate kinase 1 (GUK1) as a TKI sensitive metabolic molecule in ALK-driven lung cancer. They reported their results online in Cell on Feb. 6, 2025.